Publicacións nas que colabora con Bruno Carlos Sangro Gómez-Acebo (11)

2023

  1. Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 869-879

2022

  1. A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy

    Digestive Diseases, Vol. 40, Núm. 3, pp. 322-334

  2. Immunotherapy in hepatocellular carcinoma

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 11, pp. 663-670

  3. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a phase 2, single-arm study

    Journal for immunotherapy of cancer, Vol. 10, Núm. 11

2021

  1. Inmunoterapia en hepatocarcinoma

    Revisiones en Cancer, Vol. 35, Núm. 5, pp. 300-312

  2. Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice

    European Journal of Radiology, Vol. 135

2020

  1. Hepatic Flow Redistribution is Feasible in Patients with Hepatic Malignancies Undergoing Same-Day Work-Up Angiography and Yttrium-90 Microsphere Radioembolization

    CardioVascular and Interventional Radiology, Vol. 43, Núm. 7, pp. 987-995

  2. Lymphocytes, Neutrophils and the Response to Selective Internal Radiation Therapy: More Questions than Answers Yet

    CardioVascular and Interventional Radiology

  3. The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT

    CardioVascular and Interventional Radiology, Vol. 43, Núm. 8, pp. 1165-1172

2017

  1. Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib

    Oncotarget, Vol. 8, Núm. 61, pp. 103077-103086

2016

  1. A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib

    Liver International, Vol. 36, Núm. 8, pp. 1206-1212